vimarsana.com

Page 8 - பல்கலைக்கழகம் மருத்துவ மையம் க்ராநிகந் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Resetting the biological clock by flipping a switch

 E-Mail IMAGE: Reversible modulation of the circadian clock using chronophotopharmacology. Using light to interconvert two isomers of a photo-responsive small molecule, it is possible to pace cellular time. While irradiation with violet. view more  Credit: Issey Takahashi The biological clock is present in almost all cells of an organism. As more and more evidence emerges that clocks in certain organs could be out of sync, there is a need to investigate and reset these clocks locally. Scientists from the Netherlands and Japan introduced a light-controlled on/off switch to a kinase inhibitor, which affects clock function. This gives them control of the biological clock in cultured cells and explanted tissue. They published their results on 26 May in

This Thurs! NutraIngredients hosts Immunity & Active Nutrition webinar

This Thurs! NutraIngredients hosts Immunity & Active Nutrition webinar
nutraingredients.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nutraingredients.com Daily Mail and Mail on Sunday newspapers.

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes From AstraZenecaMay 14 2021 Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years. In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death. Image Credit: Shutterstock/Kateryna Kon AstraZeneca’s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalisation for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression.

Today! NutraIngredients hosts Immunity and Clinical Trials webinar

Today! NutraIngredients hosts Immunity and Clinical Trials webinar NutraIngredients EMEA will host its second episode of the Global Immunity Series today, investigating the body of research into immune health solutions. With immunity remaining high on the agenda for consumers and many industry players looking to tap into this burgeoning interest, NutraIngredients global team is uncovering the latest in science, innovation and regulation in a series of webinars over the coming weeks. Building on the success of our inaugural series in May 2020, the Immunity Broadcast Series 2021 provides ten category focused and regionally specific events aired between May 4th and 25th. Each webinar, hosted by the USA, APAC, and EMEA teams, will include live and interactive presentations and panel discussions with top industry experts.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.